Worawan B Limpitikul1, Ivy E Dick1, David J Tester1, Nicole J Boczek1, Pattraranee Limphong1, Wanjun Yang1, Myoung Hyun Choi1, Jennifer Babich1, Deborah DiSilvestre1, Ronald J Kanter1, Gordon F Tomaselli2, Michael J Ackerman1, David T Yue1. 1. From the Calcium Signals Laboratory, Department of Biomedical Engineering (W.B.L., I.E.D., W.Y., M.H.C., J.B., D.T.Y.) and Division of Cardiology, Department of Medicine (P.L., D.D., G.F.T.), The Johns Hopkins University School of Medicine, Baltimore, MD; Department of Physiology, The University of Maryland School of Medicine, Baltimore (I.E.D.); Division of Heart Rhythm Services, Department of Cardiovascular Diseases (D.J.T., N.J.B., M.J.A.), Division of Pediatric Cardiology, Department of Pediatrics (D.J.T., N.J.B., M.J.A.), and Windland Smith Rice Sudden Death Genomics Laboratory, Department of Molecular Pharmacology and Experimental Therapeutics (D.J.T., N.J.B., M.J.A.), Mayo Clinic, Rochester, MN; and Division of Cardiology, Nicklaus Children's Hospital, Miami, FL (R.J.K.). 2. From the Calcium Signals Laboratory, Department of Biomedical Engineering (W.B.L., I.E.D., W.Y., M.H.C., J.B., D.T.Y.) and Division of Cardiology, Department of Medicine (P.L., D.D., G.F.T.), The Johns Hopkins University School of Medicine, Baltimore, MD; Department of Physiology, The University of Maryland School of Medicine, Baltimore (I.E.D.); Division of Heart Rhythm Services, Department of Cardiovascular Diseases (D.J.T., N.J.B., M.J.A.), Division of Pediatric Cardiology, Department of Pediatrics (D.J.T., N.J.B., M.J.A.), and Windland Smith Rice Sudden Death Genomics Laboratory, Department of Molecular Pharmacology and Experimental Therapeutics (D.J.T., N.J.B., M.J.A.), Mayo Clinic, Rochester, MN; and Division of Cardiology, Nicklaus Children's Hospital, Miami, FL (R.J.K.). gtomasel@jhmi.edu ackerman.michael@mayo.edu.
Abstract
RATIONALE: Calmodulinopathies comprise a new category of potentially life-threatening genetic arrhythmia syndromes capable of producing severe long-QT syndrome (LQTS) with mutations involving CALM1, CALM2, or CALM3. The underlying basis of this form of LQTS is a disruption of Ca2+/calmodulin (CaM)-dependent inactivation of L-type Ca2+ channels. OBJECTIVE: To gain insight into the mechanistic underpinnings of calmodulinopathies and devise new therapeutic strategies for the treatment of this form of LQTS. METHODS AND RESULTS: We generated and characterized the functional properties of induced pluripotent stem cell-derived cardiomyocytes from a patient with D130G-CALM2-mediated LQTS, thus creating a platform with which to devise and test novel therapeutic strategies. The patient-derived induced pluripotent stem cell-derived cardiomyocytes display (1) significantly prolonged action potentials, (2) disrupted Ca2+ cycling properties, and (3) diminished Ca2+/CaM-dependent inactivation of L-type Ca2+ channels. Next, taking advantage of the fact that calmodulinopathy patients harbor a mutation in only 1 of 6 redundant CaM-encoding alleles, we devised a strategy using CRISPR interference to selectively suppress the mutant gene while sparing the wild-type counterparts. Indeed, suppression of CALM2 expression produced a functional rescue in induced pluripotent stem cell-derived cardiomyocytes with D130G-CALM2, as shown by the normalization of action potential duration and Ca2+/CaM-dependent inactivation after treatment. Moreover, CRISPR interference can be designed to achieve selective knockdown of any of the 3 CALM genes, making it a generalizable therapeutic strategy for any calmodulinopathy. CONCLUSIONS: Overall, this therapeutic strategy holds great promise for calmodulinopathy patients as it represents a generalizable intervention capable of specifically altering CaM expression and potentially attenuating LQTS-triggered cardiac events, thus initiating a path toward precision medicine.
RATIONALE: Calmodulinopathies comprise a new category of potentially life-threatening genetic arrhythmia syndromes capable of producing severe long-QT syndrome (LQTS) with mutations involving CALM1, CALM2, or CALM3. The underlying basis of this form of LQTS is a disruption of Ca2+/calmodulin (CaM)-dependent inactivation of L-type Ca2+ channels. OBJECTIVE: To gain insight into the mechanistic underpinnings of calmodulinopathies and devise new therapeutic strategies for the treatment of this form of LQTS. METHODS AND RESULTS: We generated and characterized the functional properties of induced pluripotent stem cell-derived cardiomyocytes from a patient with D130G-CALM2-mediated LQTS, thus creating a platform with which to devise and test novel therapeutic strategies. The patient-derived induced pluripotent stem cell-derived cardiomyocytes display (1) significantly prolonged action potentials, (2) disrupted Ca2+ cycling properties, and (3) diminished Ca2+/CaM-dependent inactivation of L-type Ca2+ channels. Next, taking advantage of the fact that calmodulinopathy patients harbor a mutation in only 1 of 6 redundant CaM-encoding alleles, we devised a strategy using CRISPR interference to selectively suppress the mutant gene while sparing the wild-type counterparts. Indeed, suppression of CALM2 expression produced a functional rescue in induced pluripotent stem cell-derived cardiomyocytes with D130G-CALM2, as shown by the normalization of action potential duration and Ca2+/CaM-dependent inactivation after treatment. Moreover, CRISPR interference can be designed to achieve selective knockdown of any of the 3 CALM genes, making it a generalizable therapeutic strategy for any calmodulinopathy. CONCLUSIONS: Overall, this therapeutic strategy holds great promise for calmodulinopathy patients as it represents a generalizable intervention capable of specifically altering CaM expression and potentially attenuating LQTS-triggered cardiac events, thus initiating a path toward precision medicine.
Authors: Ashish Kapoor; Rajesh B Sekar; Nancy F Hansen; Karen Fox-Talbot; Michael Morley; Vasyl Pihur; Sumantra Chatterjee; Jeffrey Brandimarto; Christine S Moravec; Sara L Pulit; Arne Pfeufer; Jim Mullikin; Mark Ross; Eric D Green; David Bentley; Christopher Newton-Cheh; Eric Boerwinkle; Gordon F Tomaselli; Thomas P Cappola; Dan E Arking; Marc K Halushka; Aravinda Chakravarti Journal: Am J Hum Genet Date: 2014-05-22 Impact factor: 11.025
Authors: Lia Crotti; Christopher N Johnson; Elisabeth Graf; Gaetano M De Ferrari; Bettina F Cuneo; Marc Ovadia; John Papagiannis; Michael D Feldkamp; Subodh G Rathi; Jennifer D Kunic; Matteo Pedrazzini; Thomas Wieland; Peter Lichtner; Britt-Maria Beckmann; Travis Clark; Christian Shaffer; D Woodrow Benson; Stefan Kääb; Thomas Meitinger; Tim M Strom; Walter J Chazin; Peter J Schwartz; Alfred L George Journal: Circulation Date: 2013-02-06 Impact factor: 29.690
Authors: François St-Pierre; Jesse D Marshall; Ying Yang; Yiyang Gong; Mark J Schnitzer; Michael Z Lin Journal: Nat Neurosci Date: 2014-04-22 Impact factor: 24.884
Authors: F Ann Ran; Le Cong; Winston X Yan; David A Scott; Jonathan S Gootenberg; Andrea J Kriz; Bernd Zetsche; Ophir Shalem; Xuebing Wu; Kira S Makarova; Eugene V Koonin; Phillip A Sharp; Feng Zhang Journal: Nature Date: 2015-04-01 Impact factor: 49.962
Authors: Guo Yin; Faisal Hassan; Ayman R Haroun; Lisa L Murphy; Lia Crotti; Peter J Schwartz; Alfred L George; Jonathan Satin Journal: J Am Heart Assoc Date: 2014-06-23 Impact factor: 5.501
Authors: Robert Petryszak; Tony Burdett; Benedetto Fiorelli; Nuno A Fonseca; Mar Gonzalez-Porta; Emma Hastings; Wolfgang Huber; Simon Jupp; Maria Keays; Nataliya Kryvych; Julie McMurry; John C Marioni; James Malone; Karine Megy; Gabriella Rustici; Amy Y Tang; Jan Taubert; Eleanor Williams; Oliver Mannion; Helen E Parkinson; Alvis Brazma Journal: Nucleic Acids Res Date: 2013-12-04 Impact factor: 16.971
Authors: Lia Crotti; Carla Spazzolini; David J Tester; Alice Ghidoni; Alban-Elouen Baruteau; Britt-Maria Beckmann; Elijah R Behr; Jeffrey S Bennett; Connie R Bezzina; Zahurul A Bhuiyan; Alpay Celiker; Marina Cerrone; Federica Dagradi; Gaetano M De Ferrari; Susan P Etheridge; Meena Fatah; Pablo Garcia-Pavia; Saleh Al-Ghamdi; Robert M Hamilton; Zuhair N Al-Hassnan; Minoru Horie; Juan Jimenez-Jaimez; Ronald J Kanter; Juan P Kaski; Maria-Christina Kotta; Najim Lahrouchi; Naomasa Makita; Gabrielle Norrish; Hans H Odland; Seiko Ohno; John Papagiannis; Gianfranco Parati; Nicole Sekarski; Kristian Tveten; Matteo Vatta; Gregory Webster; Arthur A M Wilde; Julianne Wojciak; Alfred L George; Michael J Ackerman; Peter J Schwartz Journal: Eur Heart J Date: 2019-09-14 Impact factor: 29.983
Authors: Alexandra Dainis; Kathia Zaleta-Rivera; Alexandre Ribeiro; Andrew Chia Hao Chang; Ching Shang; Feng Lan; Paul W Burridge; W Robert Liu; Joseph C Wu; Alex Chia Yu Chang; Beth L Pruitt; Matthew Wheeler; Euan Ashley Journal: Physiol Genomics Date: 2020-06-22 Impact factor: 3.107
Authors: Lisa M Wren; Juan Jiménez-Jáimez; Saleh Al-Ghamdi; Jumana Y Al-Aama; Amnah Bdeir; Zuhair N Al-Hassnan; Jyn L Kuan; Roger Y Foo; Franck Potet; Christopher N Johnson; Miriam C Aziz; Gemma L Carvill; Juan-Pablo Kaski; Lia Crotti; Francesca Perin; Lorenzo Monserrat; Paul W Burridge; Peter J Schwartz; Walter J Chazin; Zahurul A Bhuiyan; Alfred L George Journal: Circ Genom Precis Med Date: 2019-08-27
Authors: Priyanka Garg; Vivek Garg; Rajani Shrestha; Michael C Sanguinetti; Timothy J Kamp; Joseph C Wu Journal: Circ Res Date: 2018-07-06 Impact factor: 17.367